Brief: Aridis Announces Exclusive License Of Suvratoxumab From AstraZeneca

Aridis Pharmaceuticals

19/07/2021 13:45

July 19 (Reuters) - Aridis Pharmaceuticals Inc  ARDS.O :
    * ARIDIS PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE OF
SUVRATOXUMAB, A PHASE 3-READY MONOCLONAL ANTIBODY, FROM
ASTRAZENECA
    * ARIDIS PHARMACEUTICALS - ARIDIS ACQUIRES GLOBAL EXCLUSIVE
RIGHTS
FOR DEVELOPMENT AND COMMERCIALIZATION OF SUVRATOXUMAB FOR ALL
INDICATIONS
    * ARIDIS PHARMACEUTICALS INC - ASTRAZENECA RETAINS RIGHTS OF
FIRST
NEGOTIATION FOR FUTURE LICENSING
    * ARIDIS PHARMACEUTICALS - WILL MAKE AN UPFRONT PAYMENT TO
ASTRAZENECA OF $11M IN CASH AND ARIDIS COMMON STOCK
    * ARIDIS PHARMACEUTICALS - ASTRAZENECA WILL ALSO RECEIVE UP
TO
FURTHER $115M ON ACHIEVEMENT OF SOME MILESTONES & TIERED
ROYALTIES ON NET SALES

Source text for Eikon:  ID:nPnW6NnQa 
Further company coverage:  ARDS.O 

 ((Reuters.Briefs@thomsonreuters.com;))